What is Romark?
Established in 1993, Romark Laboratories operates at the intersection of advanced pharmacology and clinical research. The company is primarily focused on the discovery, development, and commercialization of novel small molecule drugs designed to treat infectious diseases and various forms of cancer. By maintaining a headquarters in Tampa, Florida, Romark leverages a strategic position to oversee its global clinical development programs. The firm's market position is defined by its commitment to addressing significant unmet medical needs through rigorous scientific inquiry and a robust intellectual property portfolio, distinguishing it as a key player in the specialized biotechnology sector.
How much funding has Romark raised?
Romark has raised a total of $73.2M across 7 funding rounds:
Private Equity
$23.1M
Private Equity
$9.6M
Private Equity
$15M
Private Equity
$10.8M
Debt
$10.7M
Debt
$2M
Debt
$2M
Private Equity (2009): $23.1M, investors not publicly disclosed
Private Equity (2010): $9.6M, investors not publicly disclosed
Private Equity (2013): $15M, investors not publicly disclosed
Private Equity (2014): $10.8M featuring Williams Financial Group, International Assets Advisory, LLC, and Source Capital Group, Inc.
Debt (2015): $10.7M, investors not publicly disclosed
Debt (2020): $2M with participation from PPP
Debt (2021): $2M led by PPP
Key Investors in Romark
Williams Financial Group
A Dallas-based financial services firm managing over 6.5 billion in assets, providing comprehensive advisory and investment services to independent professionals and institutional clients.
International Assets Advisory, LLC
An independent broker-dealer established in 1982, specializing in providing robust financial infrastructure and support to institutions and financial professionals.
Source Capital Group, Inc.
A boutique investment banking firm founded in 1992 that focuses on small to medium-sized transactions, offering expertise in securities, debt financing, and investment management.
What's next for Romark?
Looking ahead, the infusion of capital is expected to accelerate Romark's late-stage clinical trials and support the commercial scaling of its therapeutic assets. As the company transitions into its next phase of growth, the focus will likely shift toward regulatory milestones and the expansion of its market footprint. The strategic deployment of these funds will be critical in maintaining the company's competitive edge in the infectious disease and oncology markets, ensuring that its pipeline remains viable for global distribution. Investors will be closely monitoring the firm's ability to translate its research-driven model into sustainable commercial success, particularly as it navigates the complexities of international healthcare regulatory landscapes.
See full Romark company page
